Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
about
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporterInhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporterVesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryParkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.Evaluation of Models of Parkinson's DiseaseMicroglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic MiceElectron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial BioenergeticsGene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian modelsIncreased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.Environmental Exposures and Parkinson's DiseaseToxin-Induced Experimental Models of Learning and Memory ImpairmentEvidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposureRegulation of the 75-kDa subunit of mitochondrial complex I by ironVesicular integrity in Parkinson's diseaseEnergy failure: does it contribute to neurodegeneration?Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primateClassic Studies on the Interaction of Cocaine and the Dopamine TransporterEnzymatic oxidation of xenobiotic chemicals.Mitochondrial dysfunction in idiopathic Parkinson disease.Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans.Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changesNeuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson diseaseGDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity.Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety.Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes.Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium.Environmental exposure, obesity, and Parkinson's disease: lessons from fat and old worms.Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS).Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineTRPC channels and their implication in neurological diseasesNew Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP(+).Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse modelMitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.Astrocytes and therapeutics for Parkinson's disease.
P2860
Q24314400-AA7E9C21-8154-4384-B302-BB55D274AAF7Q24552403-9D387A83-6435-4D0E-B990-1A41F228A8FFQ24601233-64CE406B-EEA8-4C12-AD96-C65B0BACB303Q26269955-C365066E-D79C-414A-B97B-839D520722CCQ26772843-72934EE9-5590-4ED4-B906-80898513843DQ26773064-61296877-D84F-454A-8FEE-1D1B9597BAA8Q26795417-9D0D06FD-F0F1-475D-91B3-F6E8B5785BDDQ26863375-EE22B2BA-5101-4B29-912B-684B697F6163Q27308109-D1446D0C-A0D6-477F-9AAA-E4D3E7EBBA19Q27333086-B408F83D-7CC9-4B13-B56D-F45599B66286Q28074723-FEC8E2A7-AE30-4C20-9CD8-0C06AFA77566Q28075913-F03CA8F3-DD70-4D1C-B358-663E2086E25AQ28145614-E1A87599-D56B-4A29-BA97-0E7305AA1C45Q28213601-9209E9D8-EE73-4EBC-BE65-F9A7785D16C1Q28385737-7481922B-233C-4A09-B749-F91A810293B1Q28389950-5E5B5C7A-740D-4057-9E0D-431A4638A414Q28748883-448AF209-5B9E-461C-896E-CD46CC235CF8Q30397145-F287F71B-CFEB-4546-91EE-6270FD3CEB78Q30405933-BF63E589-EC50-497C-82A3-0E8F8B604030Q30446972-812F277F-76D9-42BF-A218-32FA986E77C4Q30476174-B312F8C3-37AE-4E96-86F3-852AAE893621Q30497542-C006C0DB-84DE-42F7-A55C-90F570B2A822Q30525849-9220DBB0-8793-4F9C-B572-9BAE756C54B9Q31900813-A71E2030-A162-4393-9283-9B8457704B5FQ31992475-5135ADAF-2C81-4310-8A73-75FEE4D02279Q32034638-45FB0DF8-275E-438B-BD70-284D8CDEF1DBQ32133943-0A941494-C627-405D-8500-E58B4D599AEAQ32133977-3475F040-EA38-4DCA-9E6E-0C89F4A258CBQ33191656-0A124673-4B1B-4080-A7D3-25BDC85F2B65Q33349701-2E9DF228-BB08-45DF-8129-B2DC80E784F4Q33364885-FDD1198E-9271-4B4B-8D08-3ACD4BE1BEDFQ33507513-1469FEE6-795D-4AE6-9A7D-18435DD8E3FFQ33515197-3647C083-5E47-4223-997F-41F9E60D4C8CQ33641852-9A99A68F-CC30-4A9B-A35F-D3A9DB79131DQ33757601-9AAC984F-F079-4EAD-9449-09785A5ED9BDQ33783000-DF0FD14F-B672-408D-B460-FFEB122BE52BQ33797760-F81FCEC0-DE97-44EF-A9D8-D5103F554554Q33810589-BE712E7F-A1D2-4EC8-978A-DCCD138F2BA7Q33840243-3E800BF1-FF11-48F6-BB85-3C3C3F8E9BF9Q34168266-3788E841-6093-4F0E-BDC2-21BCDE38C8CE
P2860
Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1985
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Parkinsonism-inducing neurotox ...... s explains selective toxicity.
@en
Parkinsonism-inducing neurotox ...... s explains selective toxicity.
@nl
type
label
Parkinsonism-inducing neurotox ...... s explains selective toxicity.
@en
Parkinsonism-inducing neurotox ...... s explains selective toxicity.
@nl
prefLabel
Parkinsonism-inducing neurotox ...... s explains selective toxicity.
@en
Parkinsonism-inducing neurotox ...... s explains selective toxicity.
@nl
P2860
P356
P1476
Parkinsonism-inducing neurotox ...... s explains selective toxicity.
@en
P2093
J A Javitch
R J D'Amato
P2860
P304
P356
10.1073/PNAS.82.7.2173
P407
P577
1985-04-01T00:00:00Z